AURIGENE ONCOLOGY LIMITED
Location
Karnataka
Founded
2001-08-10
Website
Risk Signals
7 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about AURIGENE ONCOLOGY LIMITED
Live alerts from global media, monitored by Business Radar
2025-04-29 (biotecnika.org)
Aurigene Oncology Biotech Research Jobs, Apply Now
Aurigene Oncology Biotech Research Jobs, Apply Now. Biological Sciences Jobs at Aurigene Oncology. MSc Biotech Jobs.
Read more
2025-04-21 (biotecnika.org)
Scientist – Cell & Gene Therapy Position at Aurigene Oncology in Bangalore | Apply Now!
Scientist – Cell & Gene Therapy Position at Aurigene Oncology in Bangalore | Ph.D. Genetics Jobs in India. M.Sc./M.Tech in Biotechnology Jobs
Read more
2025-04-03 (webwire.com)
Edity Therapeutics Enters into a Strategic Co-Development Partnership with Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors |
Edity Therapeutics Limited and Aurigene Oncology Limited (AOL), a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited, a clinical-stage biotechnology company, announced a strategic collaboration to create novel cell therapy medicines for difficult-to-treat solid tumors. , , , , The partnership is bolstered by government grants awarded to both companies. Aurigene Oncology secured grant from the India-Israel Industrial R&D and Technology Innovation Fund, while Edity received non-diluti...
Read more
2025-03-21 (biotecnika.org)
Research Associate – CAR-T Manufacturing Job | Aurigene Oncology Limited – Apply Now
Research Associate - CAR-T Manufacturing Job at Aurigene. Aurigene Oncology is hiring Research Associate in CAR-T Manufacturing in Bengaluru
Read more
2025-01-23 (businesswire.com)
Dr. Reddy’s Q3 & 9MFY25 Financial Results | Business Wire
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.
Read more
2024-09-16 (expresshealthcare.in)
ICMR signs agreements for first-in-human clinical trials of four new molecules –
ICMR partners with industry leaders for trials on molecules targeting multiple myeloma, Zika, influenza, and chronic lymphocytic leukaemia
Read more
2022-12-16 (financialexpress.com)
Dr. Reddy's subsidiary Aurigene Oncology halts clinical trials of its psoriasis drug in US - Healthcare News | The Financial Express
The company announced that it will be closing the clinical development of AUR101 in psoriasis.
Read more
(bioworld.com)
Aurigene Oncology reports potent and selective degraders of SMARCA2 and SMARCA4 as cancer therapeutics |
At the recently concluded AACR-NCI-EORTC meeting in Boston, Aurigene Oncology Ltd. reported the identification and optimization of paralogue selective degraders of SMARCA2 (AU-SM2-1) and SMARCA4 (AU-SM4-1), developed using the ALMOND-guided designing strategy, for the potential treatment of various cancers.
Read more
(cnbctv18.com)
Dr Reddy's unit achieves trial breakthrough: Positive results for blood cancer treatment - CNBC TV18
"The results from the trial in heavily pre-treated relapsed refractory myeloma patients are very exciting for us in India," said Murali Ramachandra, CEO of Aurigene Oncology. "We are thrilled with the data, as the drug could be transformative for Indian patients with myeloma."
Read more
(indiatimes.com)
Aurigene: Dr Reddy’s R&d Arm Is Now Aurigene Oncology | Hyderabad News - Times of India
Dr Reddy’s Laboratories’ wholly-owned arm Aurigene Discovery Technologies has rechristened itself as Aurigene Oncology in line with its focus on smal
Read more
(indiatimes.com)
Dr Reddy's Laboratories Secures Phase-2 Trial Approval for Groundbreaking CAR-T Cell Therapy | Hyderabad News - Times of India
Dr Reddy's Laboratories' subsidiary, Aurigene Oncology, has been authorized by the DCGI to initiate phase-2 trials for Ribrecabtagene autoleucel, a novel CAR-T cell therapy targeting multiple myeloma, showing promising results from earlier trials.
Read more